Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 974.15B, Eli Lilly(LLY) trades at $1,028.94. The stock has a price-to-earnings ratio of 50.53 and currently yields dividends of 56.8%.
During the trading session on 2025-11-18, Eli Lilly(LLY) shares reached a daily high of $1,040.72 and a low of $1,013.45. At a current price of $1,028.94, the stock is +1.5% higher than the low and still -1.1% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 3.43M, versus its average volume of 5.18M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,040.72 and a low of $623.78.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,040.72 and a low of $623.78.
LLY News
Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lil...
Mangoceuticals, Inc. recently announced the launch of MangoRx Direct and PeachesRx Direct programs, offering direct access to Eli Lilly's Zepbound and Novo Nord...
Eli Lilly’s weight-loss drug Zepbound is on track to be the world’s top-selling drug, and Lilly is inching closer to a $1 trillion market cap. Biopharma is bac...
Analyst ratings
74%
of 31 ratingsMore LLY News
Key Points Weight loss pills could account for 25% of the market share over the long term. The GLP-1 market is expected to grow to $100 billion by 2030. New...
Eli Lilly’s (LLY) Alzheimer’s disease drug, donanemab, has been approved by India’s drug regulator and is expected to be launched within the next few months. D...
JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly (LLY) to $1,150 from $1,050 and keeps an Overweight rating on the shares after meeting...
Eli Lilly now captures a clear majority of new obesity-drug prescriptions. Peter Byrne/Zuma Press The trillion-dollar club has become crowded with mostly tech...
This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...
Key Points Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go a...
Something big is happening in healthcare, as pharma stocks have recently rallied on breakthrough AI developments that could reshape the entire industry. The He...
